# A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients

> **NCT00811577** · PHASE2 · COMPLETED · sponsor: **Capstone Therapeutics** · enrollment: 150 (actual)

## Conditions studied

- Scar Prevention
- Scar Reduction

## Interventions

- **DRUG:** Placebo
- **DRUG:** AZX100

## Key facts

- **NCT ID:** NCT00811577
- **Lead sponsor:** Capstone Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2012-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00811577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00811577, "A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00811577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*